Rheumatoid Arthritis: Symptoms, Causes, How Hydroxychloroquine and DMARDs Work and Complete 2026 Treatment Guide
Rheumatoid arthritis (RA) is the most common autoimmune inflammatory joint disease in the United States — affecting approximately 1.5 million Americans and an estimated 0.5–1% of adults globally. It is 2.5 times more common in women than in men, and while it can develop at any age, onset most frequently occurs between 30 and 60 years. Unlike osteoarthritis — which is primarily a disease of cartilage wear — rheumatoid arthritis is a systemic autoimmune condition driven by the immune system attacking the body's own joint lining (synovium), causing chronic inflammation that progressively destroys cartilage, bone, and surrounding joint structures.
The fundamental message of modern rheumatology is clear: joint damage from rheumatoid arthritis is largely irreversible. Every week of uncontrolled inflammation represents ongoing damage to joint cartilage and bone — damage that accumulates silently until it manifests as permanent deformity and disability. This is why the cornerstone of RA management in 2026 is "treat-to-target" — aggressive early treatment aimed at achieving remission or minimal disease activity — rather than waiting for symptoms to become intolerable.
The 2026 American College of Rheumatology (ACR) guidelines confirm that disease-modifying antirheumatic drugs (DMARDs) — not just pain relievers — must be started as early as possible. Hydroxychloroquine (HCQS/Plaquenil) is now the ACR-recommended first-line treatment for low disease activity RA, while methotrexate remains the anchor treatment for moderate-to-high disease activity. Understanding these distinctions, how each drug class works, and what monitoring is required is essential for every patient with RA.
MedlinePlus provides comprehensive patient information on rheumatoid arthritis symptoms, diagnosis, and treatment at: https://medlineplus.gov/rheumatoidarthritis.html
What is Rheumatoid Arthritis? — The Autoimmune Mechanism
Rheumatoid arthritis is not simply joint inflammation — it is a systemic autoimmune disease where an aberrant immune response attacks the body's own tissues, primarily targeting the synovium (the thin membrane lining the joints) while also potentially affecting the heart, lungs, eyes, skin, and blood vessels.
How RA damages joints:
1. Autoimmune trigger: In genetically susceptible individuals, an environmental trigger (most commonly smoking — the strongest modifiable risk factor for RA) activates the immune system against self-antigens. Cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF) are produced — both are diagnostic markers of RA and can appear years before joint symptoms develop.
2. Synovial inflammation: Immune cells (predominantly T-cells, B-cells, and macrophages) infiltrate the synovial membrane, producing pro-inflammatory cytokines — particularly tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 (IL-1). These cytokines drive chronic inflammation, causing warmth, swelling, stiffness, and pain in affected joints.
3. Pannus formation: The inflamed synovium thickens abnormally — forming a destructive tissue called pannus. Pannus is highly vascularised and metabolically active. It invades and erodes cartilage and subchondral bone directly.
4. Irreversible joint damage: Bone erosions and cartilage loss accumulate with every episode of uncontrolled inflammation. Once damaged, joint structures do not regenerate — producing permanent deformity, instability, and loss of function.
Systemic effects beyond joints:
RA is a systemic disease. Uncontrolled RA significantly increases the risk of cardiovascular disease (by 2–3 fold — equivalent to the cardiovascular risk of type 2 diabetes), accelerates atherosclerosis, increases infection risk, and is associated with interstitial lung disease, anaemia, osteoporosis, and depression.
Recognising RA — Symptoms and Diagnosis
Classic symptoms:
Morning stiffness lasting more than 1 hour — a hallmark feature; distinguishes RA from osteoarthritis (which produces shorter stiffness); the duration reflects the degree of synovial inflammation
Symmetrical joint involvement — both hands, both wrists, both feet involved simultaneously; asymmetric presentation is less typical of RA
Small joint predilection — proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints of the fingers, wrists, metatarsophalangeal (MTP) joints of the feet — the "knuckle" joints rather than fingertips (which differentiates from psoriatic arthritis)
Warmth, swelling, and tenderness of affected joints
Fatigue — often severe; the fatigue of RA is driven by chronic systemic inflammation and is distinct from muscular tiredness
Rheumatoid nodules — firm subcutaneous lumps over bony prominences (elbows, fingers); occur in approximately 20% of RA patients and are associated with RF-positive disease
Systemic symptoms — low-grade fever, weight loss, malaise
Diagnostic workup — blood tests and imaging:
Rheumatoid factor (RF) — positive in approximately 70–80% of RA patients; not specific to RA (present in other conditions); seropositive RA generally has worse prognosis than seronegative
Anti-CCP antibodies (anti-cyclic citrullinated peptide) — more specific for RA than RF; can be positive years before symptoms; seropositivity predicts more aggressive joint damage
CRP and ESR — elevated in active RA; useful for monitoring treatment response
Full blood count — anaemia of chronic disease common in active RA
X-rays — may be normal in early RA; reveal erosions and joint space narrowing in established disease
MRI and ultrasound — detect synovitis and bone erosions earlier than X-ray; useful in early or diagnostically challenging cases
The 2010 ACR/EULAR classification criteria for RA incorporate joint involvement pattern, serological markers, inflammatory markers, and symptom duration — enabling earlier diagnosis and treatment initiation than previous criteria.
DMARD Therapy — The Foundation of RA Treatment
Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of RA treatment — they address the underlying immune dysregulation rather than simply masking pain. Unlike NSAIDs and corticosteroids (which reduce inflammation symptomatically), DMARDs slow or halt the progression of joint damage.
Three categories of DMARDs:
1. Conventional synthetic DMARDs (csDMARDs) — first-line; oral; established evidence base
2. Biologic DMARDs (bDMARDs) — injectable or infused; target specific cytokines or immune cells; used when csDMARDs are insufficient
3. Targeted synthetic DMARDs (tsDMARDs) — oral; JAK inhibitors; new class; used when biologics are insufficient or not tolerated
Hydroxychloroquine (HCQS) — First-Line for Low Disease Activity RA
Hydroxychloroquine — available as HCQS (generic) or Plaquenil (brand) — is an antimalarial drug with well-established immunomodulatory properties that make it the ACR's recommended first-line treatment for RA patients with low disease activity:
How hydroxychloroquine works in RA:
Accumulates in lysosomes of immune cells — raising lysosomal pH and interfering with antigen processing by antigen-presenting cells
Reduces activation of Toll-like receptors (TLRs) — reducing the innate immune response that drives autoimmune inflammation
Inhibits production of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) — the same mediators responsible for synovial inflammation in RA
Anti-thrombotic effect — reduces platelet aggregation; cardiovascular benefit particularly relevant given RA's elevated cardiovascular risk
Clinical evidence:
A comprehensive systematic review of HCQ therapy in RA patients (NIH PMC, 2021) confirmed HCQ's efficacy in reducing inflammation, improving lipid profile (reducing cardiovascular risk), and providing renal-protective effects in RA-associated chronic kidney disease. Triple therapy combining HCQ + methotrexate + sulfasalazine is as effective as adding a biologic in patients who fail methotrexate monotherapy — a major clinical finding that has significant cost implications.
ACR guideline recommendation (2022 update):
Low disease activity RA: hydroxychloroquine is the first recommended treatment — better tolerated and lower risk profile than methotrexate or leflunomide
Standard dose: 200–400mg daily; must not exceed 5mg/kg of actual body weight per day — the dose-limiting rule that prevents retinal toxicity
Critical safety monitoring — retinal toxicity:
Hydroxychloroquine deposits in the retinal pigment epithelium with long-term use — potentially causing irreversible bull's eye maculopathy (central vision loss) if screening is neglected. This is the most important safety concern:
Baseline ophthalmological examination before or within 1 year of starting HCQ
Annual retinal screening after 5 years of use (every 1–2 years if high-risk: renal disease, high daily dose, long duration)
Screening tool: automated visual field testing + optical coherence tomography (OCT) — both required; one test alone is insufficient
Symptoms to report immediately: difficulty reading, distorted vision, seeing halos, colour vision changes — do not wait for annual screening
TheMedicineKart stocks HCQS (hydroxychloroquine sulfate) tablets for patients with a valid prescription — the same active ingredient as Plaquenil, used in the ACR-recommended first-line treatment of low disease activity rheumatoid arthritis: [HCQS Tablets — Hydroxychloroquine]
The NIH PMC systematic review of hydroxychloroquine therapy in rheumatoid arthritis patients is available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575345/
Methotrexate — The Gold Standard for Moderate-to-High Disease Activity
Methotrexate (MTX) is the most widely prescribed DMARD globally and the ACR's recommended first-line treatment for moderate-to-high disease activity RA:
How methotrexate works:
Inhibits dihydrofolate reductase — reducing folate availability needed for rapidly dividing immune cells
Accumulates as polyglutamate forms inside cells — inhibiting additional enzymes in the folate pathway
Promotes adenosine release — producing anti-inflammatory effects through adenosine receptor activation
Net effect: reduced T-cell and B-cell proliferation; reduced cytokine production; slowed joint damage
Dosing:
Starting dose: 7.5–10mg once weekly orally (NOT daily — weekly dosing is essential; daily dosing causes severe toxicity)
Dose escalation: increase by 2.5–5mg every 4–8 weeks to 15–25mg weekly based on response and tolerance
Always prescribe with folic acid 1–5mg daily (separate day from MTX) — reduces side effects including mouth ulcers, nausea, and liver toxicity without reducing efficacy
Subcutaneous MTX: at doses above 15mg, subcutaneous injection has higher bioavailability than oral and is better tolerated
Key side effects and monitoring:
Nausea, mouth ulcers, fatigue — reduced by folic acid supplementation
Hepatotoxicity — liver function tests every 4–8 weeks initially, then every 3 months
Bone marrow suppression — full blood count monitoring
Pulmonary toxicity (MTX pneumonitis) — rare but serious; chest X-ray at baseline; report new breathlessness
Absolute contraindications: pregnancy (highly teratogenic — Category X); breastfeeding; significant renal impairment; active liver disease; alcohol dependence
Contraception: reliable contraception required for both men and women during MTX treatment and for 3 months after stopping
RA Treatment Hierarchy — Complete Comparison Table
Drug Class | Example Drugs | Disease Activity | Mechanism | Key Monitoring | Important Warnings |
Hydroxychloroquine (csDMARD) | HCQS 200–400mg daily | Low RA | Lysosomal pH change; TLR inhibition; cytokine reduction | Annual eye screening after 5 years | Retinal toxicity — irreversible if missed; never exceed 5mg/kg/day |
Methotrexate (csDMARD) | MTX 7.5–25mg WEEKLY | Moderate-High RA | Folate pathway inhibition; adenosine-mediated anti-inflammatory | LFTs, FBC every 3 months | Teratogenic (Category X); WEEKLY not daily; always add folic acid |
Sulfasalazine (csDMARD) | Azulfidine 1–3g daily | Mild-Moderate RA | Anti-inflammatory; interferes with folic acid in bacteria | FBC, LFTs | Sulfa allergy; G6PD deficiency caution |
Leflunomide (csDMARD) | Arava 10–20mg daily | Moderate RA | DHODH inhibition — reduces pyrimidine synthesis in lymphocytes | LFTs, BP | Teratogenic — 2-year drug-free period needed before pregnancy; drug persists |
TNF inhibitors (bDMARD) | Adalimumab, etanercept, infliximab | Moderate-High (MTX failure) | Block TNF-α — the primary pro-inflammatory cytokine | TB screening; infection monitoring | Reactivation of TB and hepatitis B; no live vaccines |
IL-6 inhibitors (bDMARD) | Tocilizumab, sarilumab | Moderate-High | Block IL-6 receptor — reduces acute phase response | Lipids, LFTs, FBC | Bowel perforation risk; masks fever of infection |
JAK inhibitors (tsDMARD) | Tofacitinib, baricitinib, upadacitinib | Moderate-High | Block JAK1/JAK3 — reduce cytokine signalling | FBC, lipids | FDA black box: thrombosis + malignancy + serious infection risk — use after biologic failure |
Corticosteroids (bridging only) | Prednisolone 5–10mg | Any severity — short-term | Broad anti-inflammatory — rapid but non-disease-modifying | BP, glucose, bone density | Long-term use causes osteoporosis, diabetes, infection risk — bridge only |
The Role of NSAIDs and Corticosteroids — Symptomatic Relief vs Disease Modification
A critical distinction that every RA patient must understand:
NSAIDs (ibuprofen, naproxen, celecoxib):
Reduce pain and stiffness effectively but do NOT slow joint damage. They treat symptoms only. NSAIDs are used as adjuncts to DMARD therapy — not as replacements. Regular NSAID use in RA carries risk of gastrointestinal bleeding, cardiovascular events, and renal impairment — all of which are heightened in RA patients who already have elevated cardiovascular risk.
Corticosteroids (prednisolone, methylprednisolone):
Powerful and rapid anti-inflammatory agents used as "bridge therapy" while DMARDs are initiated (DMARDs typically take 4–12 weeks to show full effect). Not disease-modifying — they do not prevent joint damage. Long-term corticosteroid use (beyond 3–6 months at significant doses) causes substantial harm: osteoporosis, steroid-induced diabetes, hypertension, adrenal suppression, infection risk, and weight gain. The goal is always to taper and stop corticosteroids once DMARDs achieve disease control.
Lifestyle and Non-Pharmacological Approaches
While DMARD therapy is the essential foundation of RA treatment, lifestyle measures significantly improve outcomes:
Exercise:
Contrary to the instinct to rest painful joints, regular low-impact exercise is one of the most evidence-based interventions in RA management — reducing fatigue, preserving muscle strength around affected joints, maintaining mobility, and improving cardiovascular health. Swimming, cycling, and walking are ideal. Exercise does not worsen joint damage in well-controlled RA.
Smoking cessation:
Smoking is the strongest modifiable risk factor for developing RA in genetically susceptible individuals and is associated with more severe, seropositive, erosive disease and worse response to treatment — including reduced efficacy of methotrexate and biologics. Smoking cessation is a therapeutic priority in RA management, not merely a general health recommendation.
Diet:
A Mediterranean diet — high in omega-3 fatty acids (oily fish, flaxseed), vegetables, legumes, and olive oil; low in processed meats and refined carbohydrates — has consistent evidence for reducing systemic inflammation and cardiovascular risk in RA patients. Weight management is important — obesity worsens RA severity and reduces DMARD efficacy.
For our complete guide on gout — frequently confused with RA; both cause joint pain and swelling but require completely different treatments: [Gout: Symptoms, Causes, Uric Acid and Treatment Guide]
For our guide on hypertension — RA patients have 2–3x elevated cardiovascular risk; blood pressure management is integral to RA care: [High Blood Pressure (Hypertension): Complete Guide]
For our guide on anxiety — depression and anxiety are 2–3 times more prevalent in people with RA than the general population, driven by chronic pain and systemic inflammation: [Anxiety Disorders: Types, Symptoms, Causes and Treatment]
The ACR Rheumatoid Arthritis treatment guidelines summary (AAFP) including the hydroxychloroquine and methotrexate recommendations is available at: https://www.aafp.org/pubs/afp/issues/2022/0900/practice-guidelines-rheumatoid-arthritis.html
Frequently Asked Questions
What is the difference between rheumatoid arthritis and osteoarthritis?
Rheumatoid arthritis (RA) is an autoimmune disease where the immune system attacks the joint lining, causing systemic inflammation, joint destruction, and extra-articular effects (cardiovascular, pulmonary, haematological). It typically affects small joints symmetrically, causes prolonged morning stiffness (over 1 hour), and occurs at any age — more commonly in women. Osteoarthritis (OA) is a degenerative joint disease caused by cartilage wear over time — most commonly affecting weight-bearing joints (knees, hips) and finger end joints (DIP joints), with minimal morning stiffness (under 30 minutes), no systemic inflammation, and typically occurring in older adults. The distinction is critical because the treatments are entirely different — DMARDs treat RA but not OA.
Is hydroxychloroquine effective for rheumatoid arthritis?
Yes — hydroxychloroquine (HCQS) is recommended by the American College of Rheumatology as the first-line treatment for patients with low disease activity rheumatoid arthritis due to its favourable efficacy, tolerability, and safety profile compared to other DMARDs. It reduces joint inflammation, improves lipid profile, reduces cardiovascular risk, and in triple therapy with methotrexate and sulfasalazine, is as effective as adding a biologic agent in patients who fail methotrexate alone. The most important safety requirement is annual retinal screening after 5 years of use, as HCQ can cause irreversible retinal damage if toxicity develops undetected.
How long does it take for DMARD treatment to work in rheumatoid arthritis?
DMARDs have a delayed onset of action — a critical expectation to set before starting treatment. Hydroxychloroquine typically takes 3–6 months to show full clinical benefit. Methotrexate typically produces meaningful improvement at 6–12 weeks, with full effect at 3–6 months. Biologics and JAK inhibitors generally produce faster responses. During this lag period, corticosteroids (prednisolone) are often used as bridge therapy to control inflammation and prevent joint damage while the DMARD builds to therapeutic effect. The lack of immediate response is not a reason to stop DMARD therapy early — premature discontinuation deprives patients of disease-modifying benefit.
Can rheumatoid arthritis be cured?
There is no cure for rheumatoid arthritis as of 2026. However, with modern treat-to-target strategies and the availability of effective DMARDs, biologics, and JAK inhibitors, achieving clinical remission — where disease activity is minimal or undetectable and joint damage progression is halted — is now a realistic goal for many patients. Approximately 20–40% of RA patients achieve sustained remission on first-line csDMARDs. Patients who achieve and maintain remission may attempt cautious dose reduction or spacing of their DMARD under rheumatological supervision. The emphasis is on early, aggressive treatment to achieve remission before irreversible joint damage accumulates.
What are the warning signs that RA treatment is not working?
Signs that current DMARD therapy is insufficient and treatment should be escalated: morning stiffness lasting more than 30 minutes despite treatment; persistent joint swelling or tenderness on examination; worsening fatigue; elevated CRP or ESR at follow-up; new bone erosions on imaging; worsening functional capacity. The treat-to-target approach requires assessment at every 1–3 monthly visit using a validated disease activity score (DAS28, CDAI, or SDAI). If the target (remission or low disease activity) is not reached within 3–6 months, treatment should be escalated — adding another csDMARD, switching to a biologic, or adding a JAK inhibitor under rheumatologist guidance.
Comments